Open Access

LIMK1: A promising prognostic and immune infiltration indicator in colorectal cancer

  • Authors:
    • Xin Liu
    • Qiang Song
    • Daohan Wang
    • Yubiao Liu
    • Zhixiang Zhang
    • Weihua Fu
  • View Affiliations

  • Published online on: May 30, 2022     https://doi.org/10.3892/ol.2022.13354
  • Article Number: 234
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Studies have shown that LIM domain kinase 1 (LIMK1) is upregulated in a variety of tumors and may be a potential detection target. The present study analyzed the expression difference of LIMK1 and its relationship with tumor clinicopathological characteristics and tumor microenvironment in colorectal cancer (CRC). The transcriptomic data of LIMK1 with CRC were downloaded from The Cancer Genome Atlas (TCGA) database and GEO databases for analyzing the expression of LIMK1 mRNA and the correlation with the prognosis of patients. The protein expression of LIMK1 was obtained from the Human Protein Atlas. The receiver operating characteristic (ROC) curve and Kaplan‑Meier was used to evaluate the expression characteristics and prognostic differences of LIMK1 in CRC. STRING was used to analyze co‑expression genes of LIMK1. The tumor immune estimation resource was applied to the correlation between LIMK1 expression and immune infiltrates. The present study verified LIMK1 expression at the level of clinical samples collected from the Tianjin Medical University General Hospital and cell lines using reverse transcription‑quantitative PCR. The mRNA and protein expression of LIMK1 were both upregulated in tumor tissues compared with adjacent tissues in CRC. The expression levels of LIMK1 were positively associated with clinical‑pathological features of CRC including lymphatic invasion (P=4.00x10‑2) and high pathologic stages (P=4.20x10‑2). The AUC value of LIMK1 in CRC was 0.937 (95% CI: 0.918‑0.957) through ROC analysis. Under the best cut‑off value (4.009), the sensitivity and specificity were 98 and 81.9%. LIMK1 expression was mainly related to CD4+ T cells, macrophages and dendritic cells in the immune microenvironment of CRC. In conclusion, the high expression of LIMK1 in CRC was closely related to the clinical features and prognosis of patients. Therefore, LIMK1 was a promising prognostic indicator and a potential target for immunotherapy in CRC.

Related Articles

Journal Cover

July-2022
Volume 24 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu X, Song Q, Wang D, Liu Y, Zhang Z and Fu W: LIMK1: A promising prognostic and immune infiltration indicator in colorectal cancer. Oncol Lett 24: 234, 2022
APA
Liu, X., Song, Q., Wang, D., Liu, Y., Zhang, Z., & Fu, W. (2022). LIMK1: A promising prognostic and immune infiltration indicator in colorectal cancer. Oncology Letters, 24, 234. https://doi.org/10.3892/ol.2022.13354
MLA
Liu, X., Song, Q., Wang, D., Liu, Y., Zhang, Z., Fu, W."LIMK1: A promising prognostic and immune infiltration indicator in colorectal cancer". Oncology Letters 24.1 (2022): 234.
Chicago
Liu, X., Song, Q., Wang, D., Liu, Y., Zhang, Z., Fu, W."LIMK1: A promising prognostic and immune infiltration indicator in colorectal cancer". Oncology Letters 24, no. 1 (2022): 234. https://doi.org/10.3892/ol.2022.13354